Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (16)
Right arrowRequest Permissions
Right arrow Disclaimer
Citing Articles
Right arrowScopus Links
Google Scholar
Right arrow Articles by Zarif, L.
Right arrow Articles by Schelling, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zarif, L.
Right arrow Articles by Schelling, J. R.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2000) 15: 1801-1807
© 2000 European Renal Association-European Dialysis and Transplant Association

Inaccuracy of clinical phenotyping parameters for hypertensive nephrosclerosis

Linda Zarif1, Adrian Covic1,2, Sudha Iyengar3, Ashwini R. Sehgal1,3, John R. Sedor1,4 and Jeffrey R. Schelling1,

1 Department of Medicine, Case Western Reserve University School of Medicine, 2 University Hospital ‘C. I. Parhon’ Iasi, Romania, 3 Department of Epidemiology and Biostatistics, and 4 Department of Physiology and Biophysics, Case Western Reserve University School of Medicine, Cleveland, OH, USA

Background. Multiple studies suggest that hypertension-induced end-stage renal disease (ESRD) is heritable. Identification of nephropathy susceptibility genes absolutely requires accurate phenotyping, but the clinical hypertensive nephrosclerosis (HN) phenotype is poorly characterized. We hypothesized that many patients with HN as the indicated cause of ESRD on the Health Care Financing Administration (HCFA) 2728 form, fail to satisfy stringent HN phenotyping criteria.

Methods. Since renal biopsy documentation of HN is uncommon, clinical parameters for HN phenotype were applied: family history of hypertension, left ventricular hypertrophy, proteinuria <0.5 g/day, and hypertension preceding renal dysfunction (Schlessinger et al., 1994) or urine protein:creatinine (prot:creat) ratio <2.0 and no evidence of other renal diseases (AASK Trial Group, 1997).

Results. ESRD patients (n=607, 73% African American, 25% Caucasian) were enrolled in a study to identify HN susceptibility genes. HN was the most common cause of ESRD according to HCFA 2728 forms (37% prevalence). Phenotyping of randomly selected patients with HN from the total cohort revealed that 4/100 subjects satisfied the Schlessinger criteria, and 28/91 African Americans met AASK criteria for HN. From these figures, the adjusted prevalence of HN was only 1.5–13.5%. Of patients that could not be phenotyped for HN, 14 were misdiagnosed, 14 had urine prot:creat >2.0, and insufficient data were available in the remainder. Four patients underwent renal biopsy, but histology from only one was consistent with HN. If the HN phenotype definitions are revised to exclude ‘hypertension preceding renal dysfunction’, or proteinuria limits, then 44/100 and 39/91 patients respectively satisfy clinical phenotyping parameters for HN.

Conclusions. (i) We provide the strongest evidence to date that HN is less frequent in an ESRD population than commonly assumed if strict clinical criteria are used; many patients clinically diagnosed with HN may have undetected, treatable renal disease from other causes; (ii) relaxing HN phenotype criteria may erroneously include patients with glomerular diseases and secondary hypertension; (iii) reliance on HCFA 2728 diagnoses will confound identification of HN susceptibility genes; (iv) to attain adequate statistical power for genotype analysis, rigorous HN phenotyping will require screening an extremely large number of patients, which can be reasonably accomplished only in a multi-centre trial design.

Keywords: diagnosis; ESRD; genes; hypertension; nephropathy; renal failure

Correspondence and offprint requests to: Jeffrey R. Schelling MD, 2500 MetroHealth Drive, G531, Cleveland, OH 44109–1998, USA.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J. Am. Soc. Nephrol.Home page
B. I. Freedman and J. R. Sedor
Hypertension-Associated Kidney Disease: Perhaps no More
J. Am. Soc. Nephrol., November 1, 2008; 19(11): 2047 - 2051.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
R. M. Salem, P. E. Cadman, Y. Chen, F. Rao, G. Wen, B. A. Hamilton, B. K. Rana, D. W. Smith, M. Stridsberg, H. J. Ward, et al.
Chromogranin A Polymorphisms Are Associated With Hypertensive Renal Disease
J. Am. Soc. Nephrol., March 1, 2008; 19(3): 600 - 614.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
C.-y. Hsu, C. E. McCulloch, J. Darbinian, A. S. Go, and C. Iribarren
Elevated Blood Pressure and Risk of End-stage Renal Disease in Subjects Without Baseline Kidney Disease
Arch Intern Med, April 25, 2005; 165(8): 923 - 928.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
B. I. Freedman, C. D. Langefeld, S. S. Rich, C. J. Valis, M. M. Sale, A. H. Williams, W. M. Brown, S. R. Beck, P. J. Hicks, and D. W. Bowden
A Genome Scan for ESRD in Black Families Enriched for Nondiabetic Nephropathy
J. Am. Soc. Nephrol., October 1, 2004; 15(10): 2719 - 2727.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
M. H. Alderman
Hypertension Control and Kidney Disease: Some Questions Answered, Many Remain
JAMA, November 20, 2002; 288(19): 2466 - 2467.
[Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.